This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Thrombocytopathy혈소판병증

ICD-10: D69.1 | Synonyms: Platelet function disorder, Qualitative platelet disorder

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Early clinical descriptions

Recognition of bleeding disorders caused by abnormal platelet function began in the early 20th century. In 1918, Glanzmann was the first to describe thrombasthenia, in which the platelet count is normal but aggregation function is lost, and this became the starting point of the concept of thrombocytopathy. Until the 1960s, platelet function disorders were classified under the general term 'thrombocytopathy'.

Development of platelet function testing

In the 1960s~1970s, with the development of light transmission aggregometry (LTA) by Born and O'Brien and others, detailed classification of platelet function disorders became possible. Subsequently, with advances in platelet membrane glycoprotein (GP) analysis, granule content analysis, and signal transduction pathway research, the molecular mechanisms of various thrombocytopathies were elucidated.

Development of the classification system

With the introduction of molecular genetic techniques in the 1990s and 2000s, the molecular classification of inherited thrombocytopathies became systematized. Thrombocytopathies are currently subdivided according to the site of the defect into membrane receptor defects, granule defects, signal transduction defects, secretion defects, and procoagulant activity defects.

Recognition in Korea

In Korea, as the infrastructure for platelet function testing has been strengthened since the 1990s, cases of diagnosed inherited thrombocytopathy are increasing. In most cases secondary (acquired) platelet dysfunction is more common, and inherited thrombocytopathies belong to the rare disease category.

2. Causes

Hereditary causes

Inherited thrombocytopathies are caused by mutations in various genes involved in platelet function.

CategoryRepresentative diseaseCausative gene
Membrane receptor defectGlanzmann thrombastheniaITGA2B, ITGB3
Membrane receptor defectBernard-Soulier syndromeGP1BA, GP1BB, GP9
Membrane receptor defectP2Y12 receptor deficiencyP2RY12
Alpha granule defectGray platelet syndromeNBEAL2
Dense granule defectHermansky-Pudlak syndromeHPS1-11
Dense granule defectChediak-Higashi syndromeLYST
Procoagulant activity defectScott syndromeTMEM16F(ANO6)

Acquired (secondary) causes

Acquired thrombocytopathies are far more common than inherited ones. Major causes include drugs (aspirin, NSAIDs, clopidogrel, ticagrelor), uremia (chronic renal failure), liver cirrhosis, dysproteinemia (multiple myeloma, Waldenström macroglobulinemia), myeloproliferative neoplasms, and extracorporeal circulation.

3. Genetics

Diversity of inheritance patterns

Inherited thrombocytopathies show various modes of inheritance depending on the type of disease. These include autosomal recessive (Glanzmann thrombasthenia, Bernard-Soulier syndrome, most storage pool deficiencies), autosomal dominant (some platelet signal transduction defects), and X-linked (some storage pool deficiencies).

List of major inherited thrombocytopathy genes

DiseaseGene (location)Mode of inheritanceKey features
Glanzmann thrombastheniaITGA2B(17q21.31), ITGB3(17q21.32)ARGPIIb/IIIa deficiency
Bernard-Soulier syndromeGP1BA(17p13.2), GP1BB(22q11.21), GP9(3q21.3)ARGiant platelets, GPIb deficiency
Gray platelet syndromeNBEAL2(3p24.3)ARAlpha granule deficiency
Hermansky-Pudlak syndromeHPS1-11ARAlbinism, pulmonary fibrosis
P2Y12 receptor deficiencyP2RY12(3q24)ARSelective loss of ADP aggregation
Scott syndromeTMEM16F(12q12)ARImpaired exposure of procoagulant phospholipids

Contribution of next-generation sequencing

With the introduction of NGS panel testing, it has become possible to identify the molecular causes of complex thrombocytopathies that were previously difficult to diagnose. Platelet function disorder NGS panels can analyze more than 30 causative genes simultaneously.

4. General epidemiology

Worldwide prevalence

The exact prevalence of inherited thrombocytopathies varies by disease type and is rare overall. Glanzmann thrombasthenia is about 1/1,000,000, Bernard-Soulier syndrome about 1/1,000,000, and storage pool deficiency is relatively more common, estimated at about 1/50,000.

Frequency of acquired platelet dysfunction

Acquired thrombocytopathy is very common. Considering only the population using aspirin, a considerable proportion of the entire adult population experiences transient platelet dysfunction. Decreased platelet function is observed in about 50% of patients with chronic renal failure and in a considerable proportion of patients with liver cirrhosis.

Status in Korea

In Korea, acquired platelet dysfunction frequently occurs due to drugs (antiplatelet agents) and chronic diseases (renal failure, liver disease). Inherited thrombocytopathies are classified as rare diseases, and accurate epidemiological statistics are lacking, but they are gradually being systematized through the rare disease registration system.

5. Pathophysiology

Stepwise abnormalities of platelet function

Platelet dysfunction can occur at several stages depending on the site of the defect.

6. Symptoms

Common bleeding symptoms

Symptoms of thrombocytopathy differ according to the type and degree of platelet dysfunction, but mucosal bleeding is commonly characteristic. Epistaxis, ecchymosis, oral gum bleeding, menorrhagia, excessive bleeding after surgery/trauma, and gastrointestinal bleeding occur.

Disease-specific symptoms

7. Signs

Physical examination findings

On physical examination, petechiae, purpura, and bruising are observed, and hepatosplenomegaly (some inherited syndromes), pallor (anemia from chronic bleeding), and albinism (Hermansky-Pudlak syndrome, Chediak-Higashi syndrome) may be found.

Blood test findings

The platelet count is mostly normal, but in Bernard-Soulier syndrome and gray platelet syndrome, mild reduction and giant platelets are observed. Bleeding time and PFA-100/200 closure time are prolonged. On platelet aggregation testing (LTA), selectively reduced response to specific agonists appears depending on the site of the defect.

Peripheral blood smear

Giant platelets (Bernard-Soulier syndrome, gray platelet syndrome), reduced intraplatelet granules (gray platelet syndrome), and giant granule neutrophils (Chediak-Higashi syndrome) appear as specific findings.

8. Screening

Clinical screening

Thrombocytopathy should be suspected in patients with recurrent mucosal bleeding despite a normal platelet count, patients with prolonged bleeding time, a history of recurrent bleeding beginning in childhood, and a family history of similar symptoms.

First-line screening tests

Complete blood count (CBC), platelet count, and peripheral blood smear are performed first. The platelet function analyzer (PFA-100/PFA-200) test is used as a simple first-line screening tool for platelet dysfunction. Coagulation tests (PT, aPTT) exclude coagulation factor abnormalities.

Exclusion of secondary causes

Acquired platelet dysfunction must be excluded by taking a medication history (aspirin, NSAIDs, antiplatelet agents), renal and liver function tests, and monoclonal protein testing.

9. Diagnosis

Light transmission aggregometry (LTA)

LTA is the standard test for diagnosing platelet dysfunction. The stage of the defect is inferred by analyzing aggregation patterns using multiple agonists such as ADP, epinephrine, collagen, arachidonic acid, and ristocetin.

Flow cytometry

Membrane glycoprotein expression (CD41/GPIIb, CD61/GPIIIa, CD42b/GPIb, CD49b/GPVI) is quantified. The activation response is evaluated using activation markers (PAC-1, P-selectin/CD62P).

Electron microscopy and granule analysis

Transmission electron microscopy (TEM) evaluates platelet ultrastructure and the number and morphology of granules. Dense granule deficiency is confirmed by mepacrine staining. ATP release assay (lumi-aggregometer) evaluates dense granule release function.

Molecular genetic testing

A gene panel suited to the suspected disease (platelet function disorder NGS panel) is performed to identify causative gene variants. Specific variants are confirmed by Sanger sequencing, and deletions/duplications are detected by MLPA.

10. Treatment

Correction of causes and removal of precipitating factors

For acquired platelet dysfunction, stopping the causative drug, treating uremia (dialysis), and treating the underlying disease take priority. In inherited cases, treatment of the underlying disease itself is limited.

Antifibrinolytic agents

Tranexamic acid is used as first-line treatment for mild bleeding and for prophylactic use before procedures. Use before mucosal bleeding, dental procedures, and minor surgery is recommended.

Desmopressin (DDAVP)

DDAVP may be effective in patients with storage pool deficiency and some platelet signal transduction defects. It improves hemostasis through release of coagulation factor VIII and vWF.

Platelet transfusion

Platelet transfusion is given for severe or life-threatening bleeding and for surgery. With repeated transfusions, HLA-matched platelets and leukoreduced platelets are used to minimize alloantibody formation.

Recombinant factor VIIa (rFVIIa)

rFVIIa is used when refractoriness to platelet transfusion develops or antibodies form. Its efficacy has been demonstrated in major inherited thrombocytopathies such as Glanzmann thrombasthenia and Bernard-Soulier syndrome.

Disease-specific treatment by underlying disease

Hermansky-Pudlak syndrome: nintedanib (FDA approved) is used when pulmonary fibrosis progresses. Chediak-Higashi syndrome and some storage pool deficiencies: allogeneic hematopoietic stem cell transplantation (HSCT) can be curative.

11. Prognosis

Prognosis by disease

The prognosis of acquired thrombocytopathy is mostly good when the cause is corrected. The prognosis of inherited thrombocytopathy differs by disease type. Pure aggregation defects (Glanzmann thrombasthenia, etc.) can have a prognosis close to a normal lifespan with appropriate management.

Prognosis of syndromic diseases

Patients with Hermansky-Pudlak syndrome often die in their 50s because of pulmonary fibrosis complications. Chediak-Higashi syndrome has a poor prognosis without HSCT when lymphohistiocytosis (accelerated phase) develops.

Effect of alloantibodies

When alloantibodies form after repeated transfusions, transfusion refractoriness develops and treatment options are limited, negatively affecting the prognosis.

12. Prevention

Avoiding bleeding-inducing drugs

Drugs that reduce platelet function, such as aspirin, NSAIDs, and clopidogrel, should be avoided. If their use is unavoidable, alternative drugs should be considered in consultation with a hematologist.

Genetic counseling

When there is a family history of inherited thrombocytopathy, genetic counseling is needed to confirm carrier status and plan pregnancy. Prenatal genetic testing (PGT-M, CVS, amniocentesis) is used when available.

Prevention of acquired causes

In patients with chronic renal failure, uremic platelet dysfunction is minimized through renal function management and optimized dialysis. Iatrogenic platelet dysfunction (drug-induced) is prevented by regular medication review.

13. References

  1. Rao AK. Inherited platelet function disorders: overview and disorders of granules, secretion, and signal transduction. Hematol Oncol Clin North Am. 2013;27(3):585-611.
  2. Nurden AT. Platelet membrane glycoproteins: a historical review. Semin Thromb Hemost. 2014;40(5):577-584.
  3. Gresele P, Harrison P, Bury L, et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost. 2014;12(9):1562-1569.
  4. Daly ME. Inherited causes of thrombocytopenia. Eur J Haematol. 2010;84(5):365-372.
  5. Hayward CP. Inherited platelet disorders. Curr Opin Hematol. 2011;18(5):357-362.
  6. Lambert MP, Ouwehand WH, Hayward CP. Rare platelet disorders. In: Gresele P, ed. Platelets in Thrombotic and Non-thrombotic Disorders. Cambridge University Press; 2017:691-715.
  7. Balduini CL, Savoia A. Genetics of familial forms of thrombocytopenia. Hum Genet. 2012;131(12):1821-1832.
  8. Lo RW, Li L, Leung R, et al. Defects in platelet signaling and their impact on anti-platelet drug discovery. Expert Opin Drug Discov. 2015;10(1):77-89.
  9. Gresele P, Bury L, Falcinelli E. Inherited platelet function disorders. In: Marder VJ et al., eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Lippincott; 2012.
  10. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24(11):1980-1987.
  11. Gunay-Aygun M, Huizing M, Gahl WA. Molecular defects that affect platelet dense granules. Semin Thromb Hemost. 2004;30(5):537-547.
  12. Solum NO. Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler Thromb Vasc Biol. 1999;19(12):2841-2846.